Usefulness of double dose contrast-enhanced magnetic resonance imaging for clear delineation of gross tumor volume in stereotactic radiotherapy treatment planning of metastatic brain tumors: a dose comparison study

The purpose of this study was to compare the size and clearness of gross tumor volumes (GTVs) of metastatic brain tumors on T1-weighted magnetic resonance images between a single dose contrast administration protocol and a double dose contrast administration protocol to determine the optimum dose of contrast-enhancement for clear delineation of GTV in stereotactic radiotherapy (SRT). A total of 28 small metastatic brain tumors were evaluated in 13 patients by intra-individual comparison of GTV measurements using single dose and double dose contrast-enhanced thin-slice (1-mm) magnetic resonance imaging (MRI). All patients had confirmed histological types of primary tumors and had undergone hypo-fractionated SRT for metastatic brain tumors. The mean tumor diameter with single dose and double dose contrast-enhancement was 12.0 ± 1.1 mm and 13.2 ± 1.1 mm respectively (P < 0.001). The mean incremental ratio (MIR) obtained by comparing mean tumor diameters was 11.2 ± 0.02 %. The mean volume of GTV-1 (single dose contrast-enhancement) and GTV-2 (double dose contrast-enhancement) was 1.38 ± 0.41 ml and 1.59 ± 0.45 ml respectively (P < 0.01). The MIR by comparing mean tumor volumes was 32.3 ± 0.4 %. The MIR of GTV-1 with < 1ml volume and GTV-1 with > 1ml volume was 41.8 ± 0.05 % and 12.4 ± 0.03 % respectively (P < 0.001). We conclude that double dose contrast-enhanced thin-slice MRI is a more useful technique than single dose contrast-enhanced thin-slice MRI, especially for clear delineation of GTVs of small metastatic brain tumors in treatment planning of highly precise SRT.

[1]  K. S. Subedi Usefulness of Double Dose Contrast-enhanced Magnetic Resonance Imaging for Clear Delineation of Gross Tumor Volume in Stereotactic Radiotherapy Treatment Planning of Metastatic Brain Tumors: A Dose Comparison Study. , 2013, Practical radiation oncology.

[2]  Jeffery A. Williams Fractionated Stereotactic Radiotherapy for Acoustic Neuromas , 2002, Stereotactic and Functional Neurosurgery.

[3]  S. Tatsuno,et al.  [Double-dose Gd-DTPA: detectability of intraparenchymal brain metastasis]. , 1996, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.

[4]  R. Onimaru,et al.  Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull. , 2003, International journal of radiation oncology, biology, physics.

[5]  W. Kenn,et al.  Enhancement of Cerebral Diseases: How Much Contrast Agent Is Enough?: Comparison of 0.1, 0.2, and 0.3 mmol/kg Gadoteridol at 0.2 T with 0.1 mmol/kg Gadoteridol at 1.5 T , 2001, Investigative radiology.

[6]  S. Lee,et al.  Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine , 2010, American Journal of Neuroradiology.

[7]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[8]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[9]  Y. Akine,et al.  Fractionated stereotactic radiotherapy of small intracranial malignancies. , 1998, International journal of radiation oncology, biology, physics.

[10]  J. Saitoh,et al.  Therapeutic effect of linac-based stereotactic radiotherapy with a micro-multileaf collimator for the treatment of patients with brain metastases from lung cancer. , 2010, Japanese journal of clinical oncology.

[11]  Willi Kalender,et al.  In vivo micro-CT imaging of rat brain glioma: A comparison with 3T MRI and histology , 2009, Neuroscience Letters.

[12]  Armin Thron,et al.  Diagnostic Accuracy of MRI Compared to CCT in Patients with Brain Metastases , 2004, Journal of Neuro-Oncology.

[13]  Norinari Honda,et al.  Measurement of repositioning accuracy during fractionated stereotactic radiotherapy for intracranial tumors using noninvasive fixation of BrainLAB radiotherapy equipment , 2006 .

[14]  J. Engh,et al.  Optimizing Intracranial Metastasis Detection for Stereotactic Radiosurgery , 2007, Stereotactic and Functional Neurosurgery.

[15]  L. Abrey,et al.  Current management of metastatic brain disease , 2009, Neurotherapeutics.

[16]  W. Yuh,et al.  The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. , 1995, AJNR. American journal of neuroradiology.

[17]  H Shirato,et al.  Magnetic resonance imaging system for three-dimensional conformal radiotherapy and its impact on gross tumor volume delineation of central nervous system tumors. , 2001, International journal of radiation oncology, biology, physics.

[18]  M. Ando,et al.  Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. , 2004, Lung cancer.

[19]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[20]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[21]  F. Lohr,et al.  Adjuvant treatment of brain metastases. , 2001, Seminars in surgical oncology.